Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

DTCM-glutarimide Delays Growth and Radiosensitizes Glioblastoma

Full text
Author(s):
Roberto, Gabriela Molinari [1] ; Paiva, Helder Henrique [2] ; Botelho de Souza, Lucas Eduardo [3] ; Pezuk, Julia Alejandra [4] ; Vieira, Gabriela Maciel [4] ; de Oliveira, Harley Francisco [5] ; Umezawa, Kazuo [6, 7] ; Tone, Luiz Gonzaga ; Brassesco, Maria Sol [1]
Total Authors: 9
Affiliation:
[1] Univ Sao Paulo, Sci & Letters Ribeirao Preto, Fac Philosophy, Dept Biol, Sao Paulo - Brazil
[2] Univ Sao Paulo, Ribeirao Preto Sch Med, Dept Internal Med, Sao Paulo - Brazil
[3] Univ Sao Paulo, Ribeirao Preto Sch Med, Reg Blood Ctr Ribeirao Preto, Sao Paulo - Brazil
[4] Univ Sao Paulo, Ribeirao Preto Sch Med, Dept Genet, Sao Paulo - Brazil
[5] Univ Sao Paulo, Ribeirao Preto Sch Med, Dept Anat, Sao Paulo - Brazil
[6] Univ Sao Paulo, Ribeirao Preto Sch Med, Dept Pediat, Sao Paulo - Brazil
[7] Aichi Med Univ, Sch Med, Dept Mol Target Med, Aichi - Japan
Total Affiliations: 7
Document type: Journal article
Source: ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY; v. 18, n. 9, p. 1323-1329, 2018.
Web of Science Citations: 0
Abstract

Background and Purpose Glioblastoma (GBM) is the most aggressive brain tumor. Even with the advent of temozolomide, patient survival remains poor, with expected median survival around 1 year from diagnosis. Consequently, the relentless search for new therapeutic strategies able to increase patient outcome persists. 3-{[}(dodecylthiocarbonyl) methyl] glutarimide (DTCM-g) is a new anti-inflammatory compound that already showed antitumor effects. Materials and Methods: Clonogenic survival, proliferation, apoptosis, cell cycle progression and invasion capacity of pediatric and adult GBM cell lines (U87MG, U251MG, SF188 and KNS-42) were evaluated under treatment with DTCM-g. The combined treatment with radiation was also evaluated in vitro and in vivo through xerographic models. Results: DTCM-g is able to impair proliferation, reduce clonogenic capacity and induce cell cycle arrest in GBM cell lines. No alteration in apoptosis rates was found after treatment. DTCM-g also reduces the invasion capacity of all GBM cell lines without alterations in MMP2 and uPa expression. Moreover, the drug radiosensitized GBM in vitro and in vivo. Conclusion: Although additional studies are still necessary to support our findings, our results suggest that DTCM-g may be a promising drug on the adjuvant treatment of GBM exhibiting antitumor effects, especially through radiosensitization. (AU)

FAPESP's process: 13/23239-9 - Evaluation of the antitumor effects of the inhibition in vitro of the AP-1 transcription factor by DTCM-g in adult and pediatric glioblastoma
Grantee:Gabriela Molinari Roberto
Support type: Scholarships in Brazil - Scientific Initiation